Physicians' opinions following pharmacogenetic testing for psychotropic medication

Walden, Lucas M.; Brandl, Eva J.; Changasi, Amtul H.; Sturgess, Jessica E.; Soibel, Alexander; Notario, Janna Fe D.; Cheema, Sheraz; Braganza, Nicole; Marshe, Victoria S.; Freeman, Natalie; Tiwari, Arun K.; Kennedy, James L.; Müller, Daniel J.

doi:10.1016/j.psychres.2015.07.032

Cited by 52 publications

(57 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Female physicians in this study had more favourable attitudes than male physicians towards the clinical application of PGx testing; this may be due to their higher level of knowledge about PGx testing compared to their male counterparts. However, other studies showed that male physicians had more favourable attitudes than female physicians towards PGx testing …”

Section: Discussionmentioning

confidence: 90%

Measuring knowledge and attitudes towards the utilization of pharmacogenetic testing among physicians

Muflih

Bleidt

Lafferty

et al. 2019

J Pharm Health Serv Res

View full text Add to dashboard Cite

Objective Pharmacogenetic (PGx) testing is a relatively new available diagnostic tool, which aims to prescribe tailored medications based on genetic differences. However, this innovation has been slowly adopted by physicians. This study aims to test Rogers's diffusion of innovation theory to assess knowledge and attitudes towards the use of PGx testing among physicians. Method A sample of community physicians in South Florida was invited to complete an online survey about PGx testing. Practicing physicians who willing to sign the participation letter were included. The survey collected data on sociodemographics, knowledge of and attitudes towards PGx testing. Multiple dimensions of knowledge (i.e. prior experience) and attitude (i.e. relative advantage) were measured. Key findings One hundred and fourty‐eight physicians participated in this study. Physicians’ actual PGx knowledge scores were averaged and significantly predicted by gender (P < 0.01), area of practice (P < 0.01) and prior experience (P < 0.05). The majority of physicians expressed optimistic attitudes towards PGx testing. Attitude scores were significantly predicted by gender (P < 0.05), the relative advantage (P < 0.05) and compatibility (P < 0.01) of testing. Barriers to PGx testing adoption including lack of insurance support, uncertainty about the clinical utility and unavailability of PGx testing at workplace were reported. Conclusions Knowledge of PGx testing among physicians was moderate despite the expressed needs and favourable attitudes. Collaborative efforts to address the potential inhibitors may foster the integration of PGx testing into clinical practice. The need for additional courses and training in the field of pharmacogenetics is warranted.

show abstract

Section: Discussionmentioning

confidence: 90%

Measuring knowledge and attitudes towards the utilization of pharmacogenetic testing among physicians

Muflih

Bleidt

Lafferty

et al. 2019

J Pharm Health Serv Res

View full text Add to dashboard Cite

show abstract

“…Personalized genetic testing may allow for personally tailored treatments, enhance diagnostic precision, and facilitate prediction of individual susceptibility to particular disorders (e.g., Thompson, Steven, & Catriona, 2015; Walden et al, 2015). However, genetic information could be misunderstood or misused, leading to discrimination, unnecessary treatments, and psychological distress (Drmanac, 2011).…”

mentioning

confidence: 99%

Testing positive for a genetic predisposition to depression magnifies retrospective memory for depressive symptoms.

Lebowitz

Ahn

2017

Journal of Consulting and Clinical Psychology

View full text Add to dashboard Cite

Objective Depression, like other mental disorders and health conditions generally, is increasingly construed as genetically based. This research sought to determine whether merely telling people that they have a genetic predisposition to depression can cause them to retroactively remember having experienced it. Method U.S. adults (men and women) were recruited online to participate (Experiment 1: N=288; Experiment 2: N=599). After conducting a test disguised as genetic screening, we randomly assigned some participants to be told that they carried elevated genetic susceptibility to depression, whereas others were told that they did not carry this elevated genetic liability or were told that they carried elevated susceptibility to a different disorder. Participants then rated their experience of depressive symptoms over the prior two weeks on a modified version of the Beck Depression Inventory-II. Results Participants who were told that their genes predisposed them to depression generally reported higher levels of depressive symptomatology over the previous two weeks, compared to those who did not receive this feedback. Conclusions Given the central role of self-report in psychiatric diagnosis, these findings highlight potentially harmful consequences of personalized genetic testing in mental health.

show abstract

“…In the precision medicine era, pharmacogenetic testing for psychotropic medication use is increasing among physicians in the United States 88 and Canada. 89 Clinicians should anticipate patients asking about pharmacogenetic testing and inform them about the current clinical applications. It is therefore important for clinicians to keep abreast of this evolving area to best facilitate informed discussions with their patients.…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenetics and Depression: A Critical Perspective

Corponi

Fabbri

Serretti

2019

Psychiatry Investig

View full text Add to dashboard Cite

Depression leads the higher personal and socio-economical burden within psychiatric disorders. Despite the fact that over 40 antidepressants (ADs) are available, suboptimal response still poses a major challenge and is thought to be partially a result of genetic variation. Pharmacogenetics studies the effects of genetic variants on treatment outcomes with the aim of providing tailored treatments, thereby maximizing efficacy and tolerability. After two decades of pharmacogenetic research, variants in genes coding for the cytochromes involved in ADs metabolism (CYP2D6 and CYP2C19) are now considered biomarkers with sufficient scientific support for clinical application, despite the lack of conclusive cost/effectiveness evidence. The effect of variants in genes modulating ADs mechanisms of action (pharmacodynamics) is still controversial, because of the much higher complexity of ADs pharmacodynamics compared to ADs metabolism. Considerable progress has been made since the era of candidate gene studies: the genomic revolution has made possible to assess genetic variance on an unprecedented scale, throughout the whole genome, and to analyze the cumulative effect of different variants. The results have revealed key information on the biological mechanisms mediating ADs effect and identified hypothetical new pharmacological targets. They also paved the way for future availability of polygenic pharmacogenetic panels to predict treatment outcome, which are expected to explain much higher variance in ADs response compared to CYP2D6 and CYP2C19 only. As the demand and availability of AD pharmacogenetic testing is projected to increase, it is important for clinicians to keep abreast of this evolving area to facilitate informed discussions with their patients. Psychiatry Investig 2019;16(9):645-653cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/bync/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Physicians' opinions following pharmacogenetic testing for psychotropic medication

Cited by 52 publications

References 18 publications

Measuring knowledge and attitudes towards the utilization of pharmacogenetic testing among physicians

Measuring knowledge and attitudes towards the utilization of pharmacogenetic testing among physicians

Testing positive for a genetic predisposition to depression magnifies retrospective memory for depressive symptoms.

Pharmacogenetics and Depression: A Critical Perspective

Contact Info

Product

Resources

About